0HS8:LSE:LSE-Caladrius Biosciences Inc. (USD)

COMMON STOCK | |

Last Closing

USD 2.195

Change

0.00 (0.00)%

Market Cap

N/A

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is in Phase 2 clinical studies for the treatment of solid tumor, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme, in combination with a range of anti-cancer regimens. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-19 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
0R2F:LSE Wells Fargo & Company

N/A

USD 9,223,372,036.85B
0R2T:LSE Micron Technology Inc

N/A

USD 9,223,372,036.85B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0M69:LSE OTP Bank Nyrt

N/A

USD 5,014.80B
0R28:LSE Newmont Corp.

N/A

USD 4,231.43B
0R2O:LSE Freeport-McMoRan Inc.

N/A

USD 4,154.37B
0QYD:LSE Yum! Brands Inc.

N/A

USD 4,109.92B
0Y4Q:LSE Willis Towers Watson PLC

N/A

USD 4,090.61B
0LD9:LSE Targa Resources Corp.

N/A

USD 4,072.69B

ETFs Containing 0HS8:LSE

EATZ AdvisorShares Restaurant .. 6.30 % 0.00 %

N/A

USD 3.90M
HAU-U:CA 3.45 % 0.00 %

N/A

N/A
PEJ Invesco Dynamic Leisure a.. 3.28 % 0.63 %

N/A

N/A
RCD Ready Capital Corporation.. 2.16 % 0.40 %

N/A

N/A
FXD First Trust Consumer Disc.. 1.42 % 0.64 %

N/A

USD 0.40B
IUSF:LSE iShares IV Public Limited.. 0.42 % 0.00 %

N/A

USD 0.31B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.42 % 0.00 %

N/A

USD 0.31B
QDVC:F iShares IV Public Limited.. 0.41 % 0.00 %

N/A

N/A
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.41 % 0.00 %

N/A

N/A
RXI iShares Global Consumer D.. 0.00 % 0.46 %

N/A

N/A
XDEW:LSE Xtrackers S&P 500 Equal W.. 0.00 % 0.00 %

N/A

N/A
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

N/A
XDEW:XETRA Xtrackers S&P 500 Equal W.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.95% N/A N/A 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.95% N/A N/A 12% F
Trailing 12 Months  
Capital Gain -18.40% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.40% N/A N/A 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 105.15% N/A N/A 95% A
Dividend Return 105.15% N/A N/A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 203.01% N/A N/A 9% A-
Risk Adjusted Return 51.80% N/A N/A 71% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike